These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
71 related articles for article (PubMed ID: 11836623)
1. Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease. Spector N; Costa MA; Morais JC; Biasoli I; Solza C; De Fatima Gaui M; Ferreira CG; Portugal RD; Loureiro M; Nucci M; Pulcheri W Oncol Rep; 2002; 9(2):439-42. PubMed ID: 11836623 [TBL] [Abstract][Full Text] [Related]
2. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease. Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564 [TBL] [Abstract][Full Text] [Related]
3. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V; J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249 [TBL] [Abstract][Full Text] [Related]
4. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
5. MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumors. Gobbi PG; Broglia C; Levis A; La Sala A; Valentino F; Chisesi T; Sacchi S; Corbella F; Cavanna L; Iannitto E; Pavone V; Molica S; Corazza GR; Federico M Clin Cancer Res; 2006 Jan; 12(2):529-35. PubMed ID: 16428496 [TBL] [Abstract][Full Text] [Related]
6. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M; J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458 [TBL] [Abstract][Full Text] [Related]
7. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373 [TBL] [Abstract][Full Text] [Related]
8. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976 [TBL] [Abstract][Full Text] [Related]
9. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A; J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521 [TBL] [Abstract][Full Text] [Related]
10. Pediatric Hodgkin's disease. Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795 [TBL] [Abstract][Full Text] [Related]
11. [Chemotherapy of BOVAPEC in the primary treatment of Hodgkin's lymphoma intermediate stages]. Raida L; Papajík T; Indrák K; Herman M; Paucek B; Zapletalová J Vnitr Lek; 2007 Jan; 53(1):31-7. PubMed ID: 17472013 [TBL] [Abstract][Full Text] [Related]
13. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V; J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100 [TBL] [Abstract][Full Text] [Related]
14. Etoposide, vinblastine, adriamycin and prednisolone (EVAP) combination chemotherapy as first-line treatment for Hodgkin's disease. Raina V; Sharma A; Mohanti BK; Kumar R; Dawar R; Rath GK Natl Med J India; 2003; 16(4):199-203. PubMed ID: 14606767 [TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial. Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171 [TBL] [Abstract][Full Text] [Related]
17. Involved-field radiotherapy for patients in partial remission after chemotherapy for advanced Hodgkin's lymphoma. Aleman BM; Raemaekers JM; Tomiŝiĉ R; Baaijens MH; Bortolus R; Lybeert ML; van der Maazen RW; Girinsky T; Demeestere G; Lugtenburg P; Lievens Y; de Jong D; Pinna A; Henry-Amar M; Int J Radiat Oncol Biol Phys; 2007 Jan; 67(1):19-30. PubMed ID: 17097834 [TBL] [Abstract][Full Text] [Related]
18. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study. Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131 [TBL] [Abstract][Full Text] [Related]
19. [Five-year outcome of a new combination chemotherapy with CEA/ABVD for advanced Hodgkin's disease with poor prognosis]. Kharchenko VP; Datsenko PV; Panyshin GA; Sotnikov VM; Mel'nik IuD Vopr Onkol; 2006; 52(5):531-7. PubMed ID: 17168361 [TBL] [Abstract][Full Text] [Related]
20. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ; J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]